Discover
VSTM
Verastem, Inc.
4.10
2 x 2.97
2 x 4.92
bid
ask
+
0.28
7.33%
2 @ 04:00 PM
4.10 +0.00 (0.00%)
| Ytd | -46.89% | |
| 1y | -15.46% |
3.83
day range
4.13
3.43
52 week range
11.25
| Open | 3.85 | Prev Close | 3.82 | Low | 3.83 | High | 4.13 | Mkt Cap | 360.28M |
| Vol | 2.18M | Avg Vol | 2.43M | EPS | -2.52 | P/E | N/A | Forward P/E | -1.57 |
| Beta | 0.14 | Short Ratio | 1.87 | Inst. Own | 59.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.56 | 200-d Avg | 6.80 | 1yr Est | 11.13 |
VSTM News
benzinga.com
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy
benzinga.com
Verastem Oncology Data From TARGET-D 101 Phase 1/2 Clinical Study Of VS-7375 Shows Encouraging Clini
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines fo
benzinga.com
Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer
Verastem updated RAMP 205 data showed 86% six-month survival in metastatic pancreatic cancer and con
benzinga.com
Verastem Announces Updated Safety, Efficacy Results From RAMP 205 Evaluating Avutometinib Plus Defac
90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis6-month overal
benzinga.com
Verastem Oncology Doses First Participant In Its TARGET-D-201 Phase 2 Registration-Directed Study Of
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines fo
benzinga.com
Verastem Oncology To Report Progress Across VS-7375 Oral KRAS G12D (ON/OFF) TARGET-D Clinical Progra
Featuring updated preliminary clinical data across tumor types from the Phase 1/2 TARGET-D 101 trial
benzinga.com
Verastem Obtains U.S. FDA Fast Track Designation For VS-7375; Phase 1 TARGET-D 101 Dose Escalation,
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines fo